Michael J. Fitzpatrick
32 IP cases indexed. Covers patent matters.
Cases Presided Over
32 cases indexed | Page 1 of 2
Guardant Health, Inc. v.Cold Spring Harbor Laboratory
Guardant Health’s IPR against the ’013 single‑cell sequencing patent resulted in the Board finding all 28 claims unpatentable as obvious over prior publications by Linnarsson and McCloskey. The petition’s obviousness arguments were accepted and the patent owner’s defenses were rejected.
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA successfully petitioned for institution in a Post-Grant Review challenging Smart Denture Conversions' dental implant patent (12156781). The Board found likelihood of unpatentability based on indefiniteness and lack of written description/enablement. This sets a precedent regarding the sufficiency of disclosure in complex medical device claims.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their dispute over U.S. Patent 11,070,530, leading to a joint motion that terminated the IPR proceeding before it was instituted.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial, leading the PTAB to terminate IPR2025-00697 and related proceedings. The settlement was documented via a Joint Stipulation for Dismissal with Prejudice filed in federal court.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health filed an IPR against Worcester Polytechnic Institute’s patent 10,653,362. The parties settled the dispute before a trial, and the Board terminated the proceeding, keeping the settlement confidential.
Zepp Health Corporation v.University of Connecticut
Zepp Health and the University of Connecticut settled their IPR dispute over Patent 10,278,647 B2. The Board granted a joint motion to terminate, ending the proceeding before trial.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to institute IPR against Seikagaku Corporation's patent (11236318) based on grounds of lack of written description and obviousness. The Board found sufficient evidence at this preliminary stage, allowing the challenge to proceed into full litigation.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to invalidate Seikagaku Corporation's patent claims related to endotoxin detection. The Board found grounds for invalidity under 35 U.S.C. § 102 and § 112, specifically citing anticipation by a prior publication.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR proceedings against Helsinn Healthcare S.A.'s anti-emetic patent (8623826). The Board found a reasonable likelihood of prevailing on independent claim 19, allowing the challenge based on obviousness over prior art like MASCC and Hoffmann.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS, INC. successfully secured institution of its IPR against Helsinn Healthcare S.A.'s patent (9186357) for anti-emetic agents. The Board found a reasonable likelihood that several claims would be unpatentable over prior art, specifically regarding the combination of triple-drug CINV treatment and superior NK antagonists.
lululemon usa inc. et al. v.Nike, Inc.
The PTAB issued a Final Written Decision finding all 21 challenged claims unpatentable. The Board determined that the prior art (Nishida and Zuckerman) anticipated or rendered obvious the claimed textile manufacturing methods, specifically regarding simultaneous knitting and planar configuration.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
Curio Bioscience, Inc.'s IPR challenge against Prognosys and 10X Genomics was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing on grounds of obviousness (over Cantor/Armani) and anticipation (by Frisen).
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding no reasonable likelihood of prevailing on grounds of anticipation (102), obviousness (103), or written description (112). The Board upheld the validity of the challenged claims in spatial omics/assay systems technology.
Curio Bioscience et al. v.Prognosys Biosciences Inc. et al.
The PTAB denied the IPR petition brought by Curio Bioscience against Prognosys and 10X Genomics, finding that the challenged claims were not obvious over Cantor or anticipated by Frisen. The Board upheld the Patent Owner's position regarding spatial analysis in tissue samples.
Garmin International, Inc. et al. v.Saris Equipment, LLC
Garmin and Saris Equipment jointly moved to end the IPR over patent 10,434,394 after reaching a settlement. The Board granted the motion, terminating the proceeding and sealing the settlement agreement.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully petitioned to institute IPR proceedings against Stratus Medical's patent, demonstrating a reasonable likelihood of success on obviousness grounds. The Board found sufficient evidence that the claimed RF neurotomy features could be achieved by combining existing prior art references.
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB found all 29 challenged claims unpatentable by a preponderance of evidence. The Board rejected the Patent Owner's argument that the invention was limited to RF neurotomy, adopting Petitioner's broader view of 'thermal ablation systems.'
Avanos Medical, Inc. v.Stratus Medical, LLC
The PTAB issued a Final Written Decision finding all 27 challenged claims unpatentable based on obviousness over prior art (Racz, Fitz, Lee). The Board adopted the Petitioner's broad definition of POSA in the field of thermal ablation systems.
Medela LLC et al. v.M.E.A.C. Engineering Ltd.
Medela and M.E.A.C. Engineering settled their IPR dispute over patent 8,858,534 B2. The Board terminated the proceeding before any trial, keeping the settlement confidential.
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
Inari Agriculture successfully petitioned to institute an IPR against Corteva Agriscience's GMO patents based on prior art from Barbour. The Board found a reasonable likelihood of prevailing regarding anticipation and obviousness over the cited publication, moving the case toward trial.
Inari Agriculture, Inc. v.Corteva Agriscience LLC et al.
The PTAB Board upheld the validity of U.S. Patent No. 8,901,378 B2 after finding that the TC1507 germplasm was publicly available prior to the application's filing date. The Board concluded that this availability satisfied priority requirements and prevented Barbour from qualifying as prior art under § 102.
Skechers U.S.A., Inc. v.Nike, Inc.
Skechers' IPR challenge against Nike regarding knit textile footwear was denied by the PTAB. The Board found no reasonable likelihood of prevailing on obviousness grounds, despite adopting the patent owner's claim construction for 'article of footwear.'
Skechers U.S.A., Inc. v.Nike, Inc.
The PTAB denied institution of an IPR petition filed by Skechers against Nike, finding the claims lacked reasonable likelihood of prevailing based on obviousness grounds (103). The Board adopted the Patent Owner's narrow construction of 'article of footwear,' which was critical to the denial.
Duration Media v.Rich Media Club LLC
The PTAB affirmed all ten claims of the ’329 ad‑viewability patent, finding Duration Media failed to prove obviousness over Krassner, Badros, and Harkins. Claim constructions on “render,” “replacement advertisement,” and the “in‑response‑to” step were adopted.
Skechers U.S.A., Inc. v.Nike, Inc.
Skechers U.S.A., Inc.'s IPR challenge against Nike, Inc.'s footwear patent was denied by the PTAB due to failure to meet the reasonable likelihood of prevailing standard. The Board rejected key claim constructions and found that prior art references did not adequately disclose the claimed integral knit tongue feature.
New Balance Athletics, Inc. v.Nike, Inc.
New Balance Athletics, Inc.'s IPR petition against Nike's footwear patent was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing in its obviousness challenges over multiple prior art references.
Solventum Corporation v.M.E.A.C. Engineering Ltd.
Solventum Corporation and M.E.A.C. Engineering reached a settlement that led to the termination of IPR2024-01001 before any trial was instituted. The Board granted the motion to terminate and ordered the settlement agreement to remain confidential.
New Balance Athletics, Inc. v.Nike, Inc.
New Balance Athletics' IPR challenge against Nike's footwear patent was denied by the PTAB. The Board rejected arguments of anticipation and obviousness, particularly regarding claim scope limitations like 'article of footwear.'
Skechers U.S.A., Inc. v.Nike, Inc.
Nike's footwear knitting patent survived Skechers' IPR challenge. The Board found no unpatentable claims after rejecting the obviousness arguments based on Reed and Nishida references.
Skechers U.S.A., Inc. v.Nike, Inc.
The PTAB institution of IPR2025-00141, filed by Skechers against Nike, moves forward to challenge the patent's validity on grounds of anticipation (102) and obviousness (103). The Board found that Petitioner demonstrated a reasonable likelihood of prevailing after vacating an initial discretionary denial.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.